Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin Ophthalmic Solution (TB0001) vs Timolol in POAG or OHT
NCT07913074Phase 2Recruiting
- Sponsor
- Tavo Biotherapeutics
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pregabalin in primary open-angle glaucoma (POAG) and ocular hypertension (4 arms), sponsored by Tavo Biotherapeutics. Primary endpoint: Change from mean diurnal baseline Intraocular Pressure to mean diurnal Intraocular Pressure at Day 28. Started Oct 2026; status: recruiting.
02
Drugs
pregabalin
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT07913074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913074.